Baseline Visual Acuity of Women with Diabetic Macular Edema is Worse than Men: A Case-Control Study
DOI:
https://doi.org/10.17140/OOJ-2-115Keywords:
Diabetic macular edema; Gender; RanibizumabAbstract
Purpose: To compare the baseline visual and anatomical parameters between the woman and
men with diabetic macular edema (DME) who underwent intravitreal ranibizumab treatment.
Materials and Methods: This was a retrospective case-control study. Treatment naïve DME
patients who were newly diagnosed and completed a follow time of 12 months in our clinic
were included. All the patients were prescribed to receive a loading dose of three consecutive monthly injections. Then the patients were followed monthly, and treated on a pro-re-nata
treatment regimen. Primary outcome measures of this study was the baseline best corrected
visual acuity (BCVA) and central retinal thickness (CRT) in the female and male patients at
the baseline. Secondary outcome measures were the change in BCVA and CRT during the 12
months follow-up period.
Results: Sixty-three eyes of 44 women, and 110 eyes of 76 men were included in the study.
The mean baseline BCVA of the women was 0.72±0.44 (range 0.1-2.0) LogMAR, and the
men was 0.49±0.31 (range 0.0-2.0) which was statistically significant between the two groups
(p<0.0001). The mean baseline CRT of the women was 484±117 microns (range 312-759),
and the men was 467±100 microns (range 320-704) (p=0.3). The mean visit number in women
and men groups were 4.6±0.9 and 4.5±1.0, respectively (p=0.5). The mean injection number in
women and men groups were 4.1±1.6 and 3.8±1.4, respectively (p=0.2).
Conclusion: Our results revealed that there may be a significant difference in baseline BCVA
between women and men with DME at the first admittance. Perhaps we should be more sensitive in periodic ophthalmology consultations of women with DME and warn the general health
care practitioners, internal medicine specialists and endocrinologists in this regard.
References
Wändell PE, Carlsson AC. Gender differences and time trends in incidence and prevalence of type 2 diabetes in Sweden--a model explaining the diabetes epidemic worldwide today? Dia-betes Res Clin Pract. 2014; 106(3): e90-e92. doi: 10.1016/j.di-abres.2014.09.013
Jiang YD, Chang CH, Tai TY, Chen JF, Chuang LM. Inci-dence and prevalence rates of diabetes mellitus in Taiwan: Anal-ysis of the 2000-2009 Nationwide Health Insurance database. J Formos Med Assoc. 2012; 111(11): 599-604. doi: 10.1016/j. jfma.2012.09.014
Leahy S, O’ Halloran AM, O’ Leary N, et al. Prevalence and correlates of diagnosed and undiagnosed type 2 diabetes melli-tus and pre-diabetes in older adults: Findings from the Irish Lon-gitudinal Study on Ageing (TILDA). Diabetes Res Clin Pract. 2015; 110(3): 241-249. doi: 10.1016/j.diabres.2015.10.015
Satman I, Omer B, Tutuncu Y, et al; TURDEP-II Study Group. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol. 2013; 28(2): 169-180. doi: 10.1007/s10654-013-9771-5
Kajiwara A, Miyagawa H, Saruwatari J, et al. Gender differ-ences in the incidence and progression of diabetic retinopathy among Japanese patients with type 2 diabetes mellitus: A clinic-based retrospective longitudinal study. Diabetes Res Clin Pract. 2014; 103(3): e7-e10. doi: 10.1016/j.diabres.2013.12.043
Al-Salameh A, Bucher S, Bauduceau B, et al. Gender-related differences in the control of cardiovascular risk factors in Pri-mary Care for Elderly Patients with Type 2 Diabetes: A Cohort Study. Can J Diabetes. 2017; pii: S1499-2671(17)30069-2. doi: 10.1016/j.jcjd.2017.08.248
Madsen TE, Khoury JC, Alwell KA, et al. Sex differences in cardiovascular risk profiles of ischemic stroke patients with dia-betes in the Greater Cincinnati/Northern Kentucky Stroke Study. J Diabetes. 2017. doi: 10.1111/1753-0407.12567
Gamboa CM, Colantonio LD, Brown TM, Carson AP, Safford MM. Race-sex differences in statin use and low-density lipo-protein cholesterol control among people with diabetes melli-tus in the reasons for geographic and racial differences in stroke study. J Am Heart Assoc. 2017; 6(5). pii: e004264. doi: 10.1161/ JAHA.116.004264
Navarro-Peternella FM, Lopes APAT, de Arruda GO, Teston EF, Marcon SS. Differences between genders in relation to fac-tors associated with risk of diabetic foot in elderly persons: A cross-sectional trial. J Clin Transl Endocrinol. 2016; 6: 30-36. doi: 10.1016/j.jcte.2016.10.001
Dąbrowski M, Szymańska-Garbacz E, Miszczyszyn Z, Dereziński T, Czupryniak L. Differences in risk factors of ma-lignancy between men and women with type 2 diabetes: A ret-rospective case-control study. Oncotarget. 2017; 8(40): 66940- 66950. doi: 10.18632/oncotarget.17716
Lindkvist EB, Kristensen LJ, Sildorf SM, et al. A Danish ver-sion of self-efficacy in diabetes self-management: A valid and reliable questionnaire affected by age and sex. Pediatr Diabetes. 2017. doi: 10.1111/pedi.12601
Patsch JM, Rasul S, Huber FA, et al. Similarities in tra-becular hypertrophy with site-specific differences in cortical morphology between men and women with type 2 diabetes mel-litus. PLoS One. 2017; 12(4): e0174664. doi: 10.1371/journal. pone.0174664
Kamoi K1, Takeda K, Hashimoto K, Tanaka R, Okuyama S. Identifying risk factors for clinically significant diabetic macula edema in patients with type 2 diabetes mellitus. Curr Diabetes Rev. 2013; 9(3): 209-217. doi: 10.2174/1573399811309030002
Klein R, Lee KE, Gangnon RE, Klein BE. The 25-year inci-dence of visual impairment in type 1 diabetes mellitus the wis-consin epidemiologic study of diabetic retinopathy. Ophthalmol-ogy. 2010; 117(1): 63-70. doi: 10.1016/j.ophtha.2009.06.051
Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema: ETDRS report No.4. Int Ophtahlmol Clin. 1987; 27: 265-272.
Ozkaya A, Alagoz C, Alagoz N, et al. Dexamethasone im-plant in pseudophakic and nonglaucomatous subgroup of dia-betic macular edema patients: A real life experience. Eur J Oph-thalmol. 2016; 26(4): 351-355. doi: 10.5301/ejo.5000725
Bressler SB, Glassman AR, Almukhtar T, et al; Diabetic Retinopathy Clinical Research Network. Five-year outcomes of ranibizumab with prompt or deferred laser versus laser or triamcinolone plus deferred ranibizumab for diabetic macular edema. Am J Ophthalmol. 2016; 164: 57-68. doi: 10.1016/j. ajo.2015.12.025
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in The Ophthalmology (TOOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.